FORM 4
[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Skorpios Trust
2. Issuer Name and Ticker or Trading Symbol

Akero Therapeutics, Inc. [ AKRO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
_____ Officer (give title below)    __X__ Other (specify below)
Former 10% owner
(Last)          (First)          (Middle)

195 ARCH. MAKARIOS III AVE., NEOCLEOUS HOUSE
3. Date of Earliest Transaction (MM/DD/YYYY)

12/1/2022
(Street)

LIMASSOL, G4 3030
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/1/2022  S(1)  1636000 D$43.50 3271829 I See Footnote (1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,346,298 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 925,531 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Skorpios Trust
195 ARCH. MAKARIOS III AVE.
NEOCLEOUS HOUSE
LIMASSOL, G4 3030



Former 10% owner
Blue Horizon Enterprise Ltd
3076 SIR FRANCIS DRAKE'S HIGHWAY
ROAD TOWN
TORTOLA, D8 



Former 10% owner
Ezbon International Ltd
3076 SIR FRANCIS DRAKE'S HIGHWAY
ROAD TOWN
TORTOLA, D8 



Former 10% owner
Montrago Trustees Ltd
195 ARCH. MAKARIOS III AVE
NEOCLEOUS HOUSE
LIMASSOL, G4 3030



Former 10% owner

Signatures
/s/ Androulla Papadopoulou, Authorized Signatory on behalf of Skorpios Trust12/5/2022
**Signature of Reporting PersonDate

/s/ Anna Maria Pavlou, Authorized Signatory on behalf of Blue Horizon Enterprise Ltd.12/5/2022
**Signature of Reporting PersonDate

/s/ Anna Maria Pavlou, Authorized Signatory on behalf of Ezbon International Limited12/5/2022
**Signature of Reporting PersonDate

/s/ Androulla Papadopoulou, Authorized Signatory on behalf of Montrago Trustees Limited12/5/2022
**Signature of Reporting PersonDate


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Akero Therapeutics Charts.
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Akero Therapeutics Charts.